---
title: "Immutep Ltd regains Nasdaq bid price compliance"
url: "https://aibio.space/news/immutep-ltd-regains-nasdaq-bid-price-compliance-after-ads-ratio-change/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-10-14"
section: "Listings"
tickers: "ASX:IMM"
source: "https://www.sec.gov/Archives/edgar/data/1506184/000119312526420840/d36112dex991.htm"
summary: "Nasdaq confirmed on October 12, 2026 that the matter is closed. The company changed its ADS ratio from 10 to 200 ordinary shares effective September 28, 20"
---

By the aibio.space news desk.

Sources

- [Immutep Ltd 6-K (2026-10-14)](https://www.sec.gov/Archives/edgar/data/1506184/000119312526420840/d36112dex991.htm)

[IMM](https://aibio.space/companies/immutep/)

2026-10-14

# Immutep Ltd regains Nasdaq bid price compliance after ADS ratio change

Tickers [IMM](https://aibio.space/companies/immutep/)

Nasdaq confirmed on October 12, 2026 that the matter is closed. The company changed its ADS ratio from 10 to 200 ordinary shares effective September 28, 2026.

## Key facts

- **Company**: Immutep Ltd (ASX: IMM)

- **News type**: Listings

- **Primary source**: [Immutep Ltd 6-K (2026-10-14)](https://www.sec.gov/Archives/edgar/data/1506184/000119312526420840/d36112dex991.htm)

*Old law books on library shelves. CC0, via rawpixel. The picture shows the field, not the companies named.*

Immutep Limited said it has regained compliance with the minimum bid price requirement of the Nasdaq Stock Market. The company announced the news on October 13, 2026, after receiving a written notice from Nasdaq dated 12 October 2026.

Nasdaq determined that the closing bid price of the company's American Depositary Shares (ADSs) was at or above US$1.00 per ADS for 10 consecutive business days, from 28 September 2026 to 9 October 2026. The rule involved is Nasdaq Listing Rule 5450(a)(1). Nasdaq has advised that the matter is now closed.

Nasdaq had notified the company by letter dated 27 April 2026 that the closing bid price of its ADSs had been below US$1.00 for 30 consecutive business days. To address the deficiency, Immutep changed the ratio of its ADSs from one ADS representing 10 ordinary shares to one ADS representing 200 ordinary shares, effective 28 September 2026.

The ratio change did not affect the ordinary shares, which continue to trade on the ASX under the code IMM. The ADSs continue to trade on the Nasdaq Global Market under the symbol IMMP.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

IMM

Immutep Ltd

ASX · Australia

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/immutep-ltd-regains-nasdaq-bid-price-compliance-after-ads-ratio-change/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Immutep Ltd regains Nasdaq bid price compliance", 2026-10-14, https://aibio.space/news/immutep-ltd-regains-nasdaq-bid-price-compliance-after-ads-ratio-change/